Scarica l'app Stockscreener
4.64
0.64%
-0.03
Dopo l'orario di chiusura:
4.87
0.23
+4.96%
Precedente Chiudi:
$4.67
Aprire:
$4.74
Volume 24 ore:
554.67K
Relative Volume:
0.60
Capitalizzazione di mercato:
$214.50M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-1.7444
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
-4.92%
1M Prestazione:
-0.64%
6M Prestazione:
-69.45%
1 anno Prestazione:
-82.48%
Intervallo 1D:
$4.53
$4.78
Intervallo di 1 settimana:
$4.53
$5.07
Portata 52W:
$4.405
$36.25
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Confronta FDMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.64 | 214.50M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
4D Molecular Therapeutics' SWOT analysis: gene therapy firm's stock faces durability test - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan Capital - MarketBeat
Peapod Lane Capital LLC Purchases New Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Jefferies cuts 4D Molecular Therapeutics target to $40 - MSN
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
FDMT stock touches 52-week low at $4.42 amid sharp annual decline - Investing.com India
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $30.00 at Chardan Capital - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Buy" Rating at HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
Gene Therapy In CNS Disorder Treatment Market Size Report 2032 | - openPR
Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at HC Wainwright - Defense World
BMO Capital Markets Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Market perform from an Outperform - Knox Daily
Jefferies cuts 4D Molecular Therapeutics target to $40 By Investing.com - Investing.com South Africa
4D’s new data in wet AMD bolster its phase III study vision - BioWorld Online
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Buy” Rating from HC Wainwright - Armenian Reporter
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
Healthy Upside Potential: 4D Molecular Therapeutics Inc (FDMT) - SETE News
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock By Investing.com - Investing.com South Africa
Barrick Gold Corp (GOLD) receives a Neutral rating from BofA Securities - Knox Daily
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts - Benzinga
ForexTV | Small Business Resources - ForexTV.com
4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMD - Nasdaq
4DMT Presents Positive 52-Week Results from Phase 2b Cohort - GlobeNewswire
There Is A Lot Of Upside Potential For 4D Molecular Therapeutics Inc(NASDAQ: FDMT) - Stocks Register
How Alibaba Stock Could Defy Trade Tariffs and Surge Higher - The Globe and Mail
Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A better buy-in window may exist right now for 4D Molecular Therapeutics Inc (FDMT) - SETE News
Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends - Citeline News & Insights
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
4D Molecular Therapeutics Inc [FDMT] Chief Legal Officer makes an insider sale of 500 shares worth $8165.0. - Knox Daily
X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, - openPR
BJ’s Wholesale Club Holdings Inc (BJ) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Allstate Corp (ALL) after recent insider movements - Knox Daily
The Potential Rise in the Price of Cardlytics Inc (CDLX) following insiders activity - Knox Daily
The Attractiveness of Investing In Bloomin Brands Inc (BLMN) is Growing - Knox Daily
Charting the Course: 4D Molecular Therapeutics Inc’s FDMT Stock Prospects - The InvestChronicle
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4DMT Announces Corporate Webcast to Review Interim 52-week - GlobeNewswire
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population - Marketscreener.com
Breakthrough Eye Treatment Data: 4D Molecular's AMD Trial Results Coming February - StockTitan
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $38.56 - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - Longview News-Journal
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):